BREAKTHROUGH: Millions with Chronic Skin Disease Gain Lifeline as Treatment Barriers Crumble!

Historic Change: Landmark CPT code revisions by the AMA dramatically expand insurance coverage for 308nm excimer laser treatments.
Vast New Access: Over 30 million U.S. patients with conditions like vitiligo, atopic dermatitis, and alopecia areata can now access treatments previously mired in red tape, up from 10 million⁷.
Hope Restored: Systemic denials and cumbersome prior authorizations are set to plummet, paving a smoother path to relief for sufferers of inflammatory and auto-immune skin diseases.

In a monumental shift that promises to transform the lives of millions, STRATA Skin Sciences (NASDAQ: SSKN) today announced that the American Medical Association (AMA) CPT Editorial Panel has accepted sweeping revisions to CPT codes 96920-96922⁷. This historic decision, effective from May 2025, shatters long-standing reimbursement barriers for 308nm excimer laser treatments, extending coverage far beyond its original psoriasis indication.

For countless individuals battling debilitating skin conditions such as vitiligo, atopic dermatitis, mycosis fungoides, lichen planus, alopecia areata, and cutaneous T-cell lymphoma (CTCL), this is the dawn of a new era. The change explicitly recognizes the broad clinical efficacy of STRATA's XTRAC® excimer laser, a safe, non-drug therapy already used in over 20 million treatments worldwide⁸. This technology, known for its targeted UVB light, offers superior clinical outcomes, including faster re-pigmentation and fewer treatment sessions⁵.

"This is the inflection point we’ve worked toward for decades," declared Dr. Dolev Rafaeli, STRATA CEO, highlighting years of advocacy and compelling clinical evidence. Previously, despite its proven success, only 30% of excimer laser procedures treated non-psoriasis conditions due to arduous pre-authorization processes⁷. Now, with a clear reimbursement path, access is unlocked for an estimated 30 million potential patients.

Experts like Dr. Lebwohl lauded the update, stating, "Phototherapy—and excimer laser in particular—has transformed the treatment landscape for vitiligo and atopic dermatitis." Dr. Grimes, President of the Global Vitiligo Foundation, hailed it as "a major victory," emphasizing that "insurance coverage has lagged behind clinical practice for too long."

This landmark change, fueled by STRATA's collaboration with leading dermatologists and patient advocates, is poised to drive significant adoption of the XTRAC platform, already present in over 1,400 U.S. clinics⁷, offering a reimbursable, effective alternative for patients and a cost-effective solution for payers.

BREAKTHROUGH: Millions with Chronic Skin Disease Gain Lifeline as Treatment Barriers Crumble!

References

Stay Updated!